Li 2016.

Methods	SIngle‐centre Non‐inferiority comparison of mEOX vs FOLFIRI RCT 2 arms: modified EOX vs FOLFIRI
Participants	105 patients (55 received EOX, 50 received FOLFIRI)
Interventions	"The EOX group was given epirubicin 50 mg/m2 iv on day one, oxaliplatin 85 mg/m2 iv on day 1 and capecitabine at a twice‐daily dose of 625 mg/m2 po for 2 wk, which was repeated every 3 wk"
Outcomes	OS PFS (separately for both first‐ and second‐line) Objective response rate Disease control rate Adverse events
Notes	Second‐line chemo allowed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not specified
Allocation concealment (selection bias)	Unclear risk	Not mentioned
Incomplete outcome data (attrition bias) efficacy	Unclear risk	Patient disposition/CONSORT flow diagram not provided; unclear how many were screened and excluded, and for what reasons
Incomplete outcome data (attrition bias) safety	Unclear risk	Patient disposition/CONSORT flow diagram not provided; unclear how many were screened and excluded, and for what reasons
Selective reporting (reporting bias)	Unclear risk	Adverse effects (NCI‐CTC) categorised and analysed as grades 1‐4 and 3‐4
Other bias	Unclear risk	N/A
Blinded review of CT/MRI‐scans?	Unclear risk	Not mentioned